MicroRNA 29b-3p (miR-29b-3p) (miR-29b-3p)

MicroRNA 29b-3p (miR-29b-3p) is a mature microRNA belonging to the miR-29 family, which plays a central role in regulating the extracellular matrix (ECM) and epigenetic modifications [1.1.1, 1.2.4]. It is widely recognized as a "master regulator" of fibrosis due to its ability to target and downregulate multiple collagen genes (e.g., COL1A1, COL3A1) and other ECM-related proteins [1.1.3, 1.2.1]. Additionally, miR-29b-3p acts as an "epi-miRNA" by directly targeting DNA methyltransferases DNMT3A and DNMT3B, thereby modulating global DNA methylation patterns and preventing the silencing of tumor suppressor genes [1.2.2, 1.2.4]. In oncology, it generally functions as a tumor suppressor by promoting apoptosis and inhibiting cell proliferation and metastasis, although its role can be context-dependent [1.2.3, 1.3.1]. Therapeutic development has focused on miR-29 mimics, such as Remlarsen (MRG-201), which aim to restore miR-29b levels to treat fibrotic diseases like cutaneous and pulmonary fibrosis [1.2.1, 1.2.5]. Beyond fibrosis and cancer, miR-29b-3p is implicated in cardiovascular and neurodegenerative diseases, where its dysregulation serves as a potential biomarker for disease progression [1.4.1, 1.4.2]. The therapeutic potential of miR-29b-3p is currently being explored in clinical and preclinical settings, focusing on its ability to reverse pathological gene expression patterns in chronic diseases [1.2.1, 1.2.4]. Its interaction with drugs like Bortezomib further highlights its role in mediating therapeutic responses through epigenetic and apoptotic pathways [1.2.4].

Other names

hsa-miR-29b-3pmiR-29bMIRN29B1MicroRNA 29b-1hsa-mir-29b-1

miR-29b-3p functions primarily through post-transcriptional gene silencing, where it binds to the 3' untranslated region (3' UTR) of target mRNAs, leading to their degradation or translational inhibition [1.1.1, 1.1.3]. Therapeutic mimics like Remlarsen work by restoring the levels of this miRNA to suppress pathological targets such as collagen (COL1A1, COL3A1) in fibrosis and anti-apoptotic factors (MCL1, BCL2) in cancer [1.2.1, 1.2.4]. It also acts as an epigenetic modulator by inhibiting DNA methyltransferases (DNMT3A, DNMT3B), which reduces DNA methylation and restores the expression of silenced tumor suppressor genes [1.2.2, 1.3.1].